Biosimilars:The US Payer Perspectives
Biosimilars continue to be big business in the US, but has progress has
been too slow? Not so, argue payers. While the number of biosimilar approvals
in the US still lags behind Europe, a solid foundation continues to be laid by
multiple key stakeholder groups. Successes have been seen in key areas,
including the approval of the first monoclonal antibody (mAb) biosimilar,
Inflectra, and regulatory refinement. But what of the critical opportunities
and challenges in the US? How do payers perceive what’s important, and what can
companies do to ensure commercial success?
WHAT FEATURES
DOES THE REPORT PROVIDES?
In-depth interviews reveal over 200 unique and candid insights from ten
10 expert US payers from government and commercial backgrounds
Overview of the key areas of progress in the US biosimilars market during
the last year, including an analysis of critical market shaping issues such as
clinical data, regulatory progress, commercialisation, legal and policy.
The key issues regarding how the US biosimilars market has evolved and
where payers believe future efforts need to be focused, including pricing,
market access and contracting.
Detailed case studies on the commercialisation of two biosimilars (Zarxio
and Inflectra) and one follow-on biologic (Basaglar), and what payers believe
has gone well and where improvements for subsequent launches need to be made.
Updated insights on what the critical challenges and opportunities within
the US biosimilars market are today, and what companies can do to navigate
these successfully.
WHAT ARE
THE KEY BENEFITS OF THE REPORT ?
Understand how the US biosimilars market has evolved over the past year
and what the stand- out developments was.
Gain insight into the trends that are set to drive high rates of
biosimilar adoption in the US, and what issues could slow this adoption down
Gain insight into the role of focused and unbiased education has on
biosimilars, and which key stakeholder group payers believe needs to be the key
focus of these educational efforts.
Assess the current views on drug pricing in the US, and what impact
biosimilars could have on lowering prices and improving patient access.
Critique payer views on the evolving arguments for switching from
originator brands to biosimilars, and how FDA regulations and state-level
legislation needs to work in concert for this to become a reality.
Navigate the critical opportunities and challenges within the US
biosimilars market, and understand what payers see as must-win battles to
ensure a successful US biosimilars market.
To view
Full Report: http://www.aarkstore.com/healthcare/186620/biosimilars-us-payer-perspectives
WHO WOULD
BENEFIT FROM THIS REPORT?
Commercial teams negotiating biosimilar prices and discounts with payers
Marketing teams communicating the benefits and safety of biosimilars
Medical affairs teams, including medical science liaisons, who are
building the evidence case for biosimilars with physicians and payers, and
engaging with physicians about biosimilar safety and efficacy
Market research and HEOR teams analysing long-term real world data on
biosimilar use and outcomes
Payer strategy teams tasked with the job of understanding what payers are
looking for from biosimilars and originator brands, and how this thinking can
be change
Get
Sample Request @ http://www.aarkstore.com/sample/186620
Table of
Content
1. Executive Summary
2. Research Objectives and Methodology
3. Overview Of Progress In The Us Market
4. Biosimilar Awareness and Education
5. The Currently Regulatory Environment
6. Key Considerations in The Commercialisation Of Biosimilars
7. Biosimilar Commercialisation Case Studies
8. Future Challenges and Opportunities
9. Appendix
More
Related Reports @ http://www.aarkstore.com/healthcare
About
Aarkstore
Aarkstore Enterprise
is a leading provider of business and financial information and solutions
worldwide. We specialize in providing online market business information on
market research reports, books, magazines, conference at competitive prices,
and strive to provide excellent and innovative service to our customers.
Contact
Details:
Aarkstore
Phone: 91 - 998 729 5242
Comments
Post a Comment